Roble Belko & Company’s Viking Therapeutics VKTX Stock Holding History

Roble Belko & Company’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25	Closed	-$1K	–	525
2025 Q3	$1K	Buy	+25	New	+$746	﹤0.01%	418

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Roble Belko & Company's VKTX Position: Q4 2025 in Review

Roble Belko & Company sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 25 shares — an estimated $1K sold.

Roble Belko & Company first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $1K in Q3 2025. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Roble Belko & Company reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Roble Belko & Company sold 25 Viking Therapeutics shares in Q4 2025, an estimated $1K.
Roble Belko & Company first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
Roble Belko & Company's Viking Therapeutics position peaked at $1K in Q3 2025.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Roble Belko & Company's 13F filing for Q4 2025, filed 12 Jan 2026.